Alteogen Inc

KOSDAQ:A196170

Güney Kore / Sağlık Hizmetleri / Biyoteknoloji

Genel Bakış

Haberler

5 Yıllık Finansal Veriler

Hisse Fiyatı

363.000,00 KRW


Key Metrics	Latest
Total Revenue	102,9 B
Adjusted EBITDA	28,254 B
EBITDA Margin	27,5%
Net Profit Margin	58,9%
Total Assets	409 B
Total Debt	11,759 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	42,425.84	38,745.94	28,806.34	96,522.93	102,854.62	102,854.62	96,522.93	102,854.62
% Growth		(0.09)	(0.26)	2.35	0.07			0.07

Adjusted EBITDA	1,810.70	(13,041.09)	(26,719.37)	(6,403.31)	28,254.38	28,254.38	(6,403.31)	28,254.38
% Margin	0.04	(0.34)	(0.93)	(0.07)	0.27	0.27	(0.07)	0.27

Adjusted EBIT	(58.17)	(15,192.01)	(29,373.68)	(9,736.84)	25,403.99	25,403.99	(9,736.84)	25,403.99
% Margin	(0.00)	(0.39)	(1.02)	(0.10)	0.25	0.25	(0.10)	0.25

Adjusted Net Income	(18,238.79)	(20,294.40)	(18,397.59)	(3,670.29)	60,568.53	60,568.53	(3,670.29)	60,568.53
% Margin	(0.43)	(0.52)	(0.64)	(0.04)	0.59	0.59	(0.04)	0.59

Adjusted Basic EPS	(362.31)	(400.97)	(358.75)	(71.05)	1,140.33	1,140.33	(71.05)	1,140.33

Destekleyen Hesaplamalar

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
KRW	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	42,426	38,746	28,806	96,523	102,855	102,855	96,523	102,855
% Growth	NA	-8.7%	-25.7%	235.1%	6.6%			6.6%

Cost of Revenue	(23,748)	(33,045)	(24,352)	(65,382)	(38,813)	(38,813)	(65,382)	(38,813)
Gross Profit	18,678	5,701	4,454	31,141	64,041	64,041	31,141	64,041
% Revenue	44.0%	14.7%	15.5%	32.3%	62.3%	62.3%	32.3%	62.3%

Research and Development	(7,691)	(7,480)	(18,660)	(25,306)	(24,550)	(24,550)	(25,306)	(24,550)
Selling and Marketing	(1,697)	(1,493)	(1,829)	(1,971)	(2,660)	(2,660)	(1,971)	(2,660)
General and Admin	(8,840)	(11,220)	(12,406)	(12,497)	(10,088)	(10,088)	(12,497)	(10,088)
Other Inc / (Exp)	(18,246)	2,337	15,026	441	2,725	2,725	441	2,725
Total Operating Exp	(36,474)	(17,856)	(17,868)	(39,333)	(34,574)	(34,574)	(39,333)	(34,574)

Operating Income	(17,796)	(12,155)	(13,413)	(8,192)	29,468	29,468	(8,192)	29,468
% Revenue	-41.9%	-31.4%	-46.6%	-8.5%	28.6%	28.6%	-8.5%	28.6%

Interest Expense	105	1,461	3,443	4,627	7,144	7,144	4,627	7,144
Pre-tax Income	(17,692)	(10,694)	(9,970)	(3,564)	36,612	36,612	(3,564)	36,612
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(583)	(893)	(108)	(18)	24,078	24,078	(18)	24,078
Net Income to Company	(18,275)	(11,588)	(10,078)	(3,582)	60,690	60,690	(3,582)	60,690
% Margin	-43.1%	-29.9%	-35.0%	-3.7%	59.0%	59.0%	-3.7%	59.0%

Minority Interest in Earnings	2,453	5,313	1,932	210	1,562	1,562	210	1,562
Net Income to Stockholders	(15,822)	(6,275)	(8,146)	(3,372)	62,252	62,252	(3,372)	62,252

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(15,822)	(6,275)	(8,146)	(3,372)	62,252	62,252	(3,372)	62,252
% Margin	-37.3%	-16.2%	-28.3%	-3.5%	60.5%	60.5%	-3.5%	60.5%

As Reported
Basic EPS (Continuing Ops)	(314.29)	(123.98)	(158.85)	(65.27)	1,172.04	1,172.04	(65.27)	1,172.04
Diluted EPS (Continuing Ops)	(314.29)	(124.00)	(159.00)	(65.27)	1,163.00	1,163.00	(65.27)	1,163.00

WA Basic Shares Out.	50.34	50.61	51.28	51.66	53.11	53.11	51.66	53.11
WA Diluted Shares Out.	50.34	50.61	51.28	51.66	53.11	53.11	51.66	53.11

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(17,692)	(10,694)	(9,970)	(3,564)	36,612	36,612	(3,564)	36,612
Addback: Net Interest Expense	(105)	(1,461)	(3,443)	(4,627)	(7,144)	(7,144)	(4,627)	(7,144)
Addback: Other Non Operating Expenses, Total	17,690	8,729	(4,718)	(1,426)	(3,899)	(3,899)	(1,426)	(3,899)
Addback: Depreciation & Amortization	1,869	2,151	2,654	3,334	2,850	2,850	3,334	2,850
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	(13,310)	(11,360)	(31)	(25)	(25)	(31)	(25)
Addback: Gain (Loss) On Sale Of Assets	81	18	(127)	(110)	0	0	(110)	0
Addback: Asset Writedown	10	1,525	528	22	15	15	22	15
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	(42)	0	(283)	0	(155)	(155)	0	(155)
Adjusted EBITDA	1,811	(13,041)	(26,719)	(6,403)	28,254	28,254	(6,403)	28,254
% Margin	4.3%	-33.7%	-92.8%	-6.6%	27.5%	27.5%	-6.6%	27.5%

Adjusted EBIT	(58)	(15,192)	(29,374)	(9,737)	25,404	25,404	(9,737)	25,404
% Margin	-0.1%	-39.2%	-102.0%	-10.1%	24.7%	24.7%	-10.1%	24.7%

Adjusted Net Income Reconciliation
Net Income to Company	(18,275)	(11,588)	(10,078)	(3,582)	60,690	60,690	(3,582)	60,690
Addback: Unusual Items	48	(11,766)	(11,243)	(119)	(165)	(165)	(119)	(165)
Less: Tax Benefit of Unusual Items (26%)	(13)	3,059	2,923	31	43	43	31	43
Adjusted Net Income	(18,239)	(20,294)	(18,398)	(3,670)	60,569	60,569	(3,670)	60,569
% Margin	-43.0%	-52.4%	-63.9%	-3.8%	58.9%	58.9%	-3.8%	58.9%

Yüklenme Hatası

Alteogen Inc

KOSDAQ:A196170

Güney Kore / Sağlık Hizmetleri / Biyoteknoloji

5 Yıllık Finansal Veriler